CRBU

Caribou Biosciences, Inc. (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company founded in 2011 and headquartered in Berkeley, California. The company went public in July 2021 and specializes in developing genome-edited allogeneic cell therapies for treating blood cancers and solid tumors. Caribou emerged from pioneering work in CRISPR gene editing technology and has positioned itself as a leader in developing off-the-shelf cellular immunotherapies that can be manufactured at scale and administered to multiple patients without requiring personalized treatment preparation.